Nice non answer. You appear to be ignorant about basic financial terms. I would suggest Investopedia. Good site.
They seemed to be spot on with GOMO. I think you'll see some VNET dominos start to fall in next couple weeks. FIrst, you'll have internal audits which will discover only minor issues. Then you'll have E&Y resign, followed by some downgrades and officer resignations. Once a Chinese company is put under a microscope, its just a matter of time.
Would think you'll have some money movement from VNET to BABA. IPO may actually hurt VNET, which some consider damaged and dead money for now.
Ebola is a dreaded virus, and there is certainly an urgency to find a vaccine and a cure. However, investors need to be careful that they do not end up in tears from buying Ebola-related stocks without fully understanding the fundamentals.There is simply too much puffery in the mainstream media to lead unsuspecting investors astray.
The latest example is an article that appeared in the Daily Mail after the market close Wednesday hyping Tekmira Pharmaceuticals Corp TKMR, +10.78% with a tantalizing title “Merger mania in healthcare sector keeps dealers on toes during peak holiday weeks with Tekmira now high on takeover tonic.”The stock took off in the aftermarket as the message boards put their faith in the piece.
The article starts out comparing Tekmira with InterMune ITMN, +0.06% and based on this comparison, concludes that Tekmira is worth about $40, more than twice the price of Tekmira stock before the article appeared.
Comparing Tekmira to InterMune is like comparing a kid's tricycle to a Ferrari.
First take a look at the annotated chart of Tekmira.
Please click here to see the annotated chart of TKMR.
The Daily Mail article omits the bad news for Tekmira — that U.S. scientists will start a trial of Ebola vaccine from Glaxo GSK, +0.28% as early as next week. The news is bad for Tekmira, in that Tekmira does not have a vaccine, but a potential drug in very early stages of development. If a vaccine is successful, there will obviously be less need for an Ebola drug.
Seems to move up on hype, will short if it moves up much more, probably somewhere between 23 and 25.
Would probably buy if it heads down to $15-16 or so. Decent company, just too many people jumping on Ebola bandwagon, which is not where much money is to be made. Too little dollars, and too many competitors.
Agree with EXAS, but TKMR may fall again, since it keeps getting the ebola hype buyers who run away when they see the competition ( and dont see any upside near term ).
Both will probably be up and down for awhile.
Camera's are more of a commodity, but at least Taser is trying to diversify. Dont know why they dont have dashcams, etc. like the competition does. Anyone know where the Taser camera's are made? Is it Asia?
Also think youre probably right. GoPro had a great, well priced IPO and they rocketed. It had been overbought and subsequently adjusted in one day from near 50 to just under 42 currently. Not sure what that bodes for ZAGG, but at least you have a theory.
Probably a good move, Zagg has made an interesting move up but I doubt it is sustainable. Several factors working against them now, and they are in what has become a commodity industry.